Summary and Investment Conclusion On net, drug manufacturers are using co-pay cards to reduce the higher out-of-pocket (OOP) costs faced by beneficiaries on the health insurance exchanges (HIEs) as compared…
Premise and rationale Share prices of drug and biotech stocks arguably can be broken down into two major components: the capital markets’ estimates of the value of assets that are…
Background and Rationale Drug, biotech, and research-based spec pharma stocks tend to outperform their peers in the periods preceding and following the anticipated approval of major new branded products. The…
Summary and Conclusions The prescription drug formularies of health plans sold on the Affordable Care Act’s (ACA’s) public health insurance exchanges (HIEs) are significantly more restrictive than the drug formularies…
Premise and rationale Share prices of drug and biotech stocks arguably can be broken down into two major components: the capital markets’ estimates of the value of assets that are…
Premise and rationale behind the ‘Hidden Pipeline’ valuation method Share prices of drug and biotech stocks arguably can be broken down into two major components: the capital markets’ estimates of…
Background Product pipelines account for a large percentage of drug and biotech companies’ total values, however relatively little information about pipeline products is available through traditional sources. As a result,…
Background and Introduction Pharmaceuticals demand growth is the product of population growth, growth in units (e.g. prescriptions) per person, and growth in price per unit. Price per unit can be…